Clinical Trial

A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-16.
Status change: Not Yet Recruiting → Recruiting 2025-11-24
Trial Details
NCT Number NCT07083323
Lead Sponsor Sichuan Huiyu Pharmaceutical Co., Ltd
Collaborators: Peking University Cancer Hospital & Institute
Conditions Advanced Solid Tumor
Enrollment 262 participants
Start Date 2025-07-22
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-25